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Introduction – general aspects
Clinical presentation
Pheochromocytomas are rare tumors usually 
characterized by secretion of catecholamines and 
associated signs and symptoms of catecholamine 
excess. This secretion can arise in a sudden burst 
leading to paroxysmal symptoms. The classical 
symptom triad consists of palpitations, headaches 
and sweating lasting from only minutes to hours 
and occurring periodically on different occasions 
[Manger et al., 1996]. Other symptoms, especially 
in an acute attack, include pallor, nausea and 
panic attacks, which may last for several minutes 
and resolve completely.
Apart from the above classic presentation, pheo-
chromocytoma can also present with nonspecific 
symptoms such as flushing, nausea, tiredness or 
weight loss. Abdominal pain and constipation or 
chest pain mimicking myocardial infarction as in 
the case of inverted takotsubo cardiomyopathy 
can be caused by sudden catecholamine release 
[Prejbisz et al., 2011]. A subtle sign may be new 
onset of diabetes, particularly in the young non-
obese patient [La Batide-Alanore et al., 2003]. 
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Due to the diverse clinical manifestations, 
pheochromocytoma is therefore often referred as 
one of the great mimics in medicine. The first 
step in management of pheochromocytoma is to 
think of this rare disease and to then make the 
diagnosis [Manger, 2006].
Hypertension and incidentaloma
Pheochromocytoma is a rare cause of hyperten-
sion, but important because it is a usually curable 
cause of high blood pressure. The prevalence 
of the tumor among 4429 patients investigated 
for possible secondary hypertension has been 
reported at 0.3% [Anderson et al., 1994]. This is 
still higher than revealed in large autopsy studies, 
where the prevalence ranged from 0.05 to 
0.09% in 44,680 and 15,984 deceased individu-
als respectively [Minno et al., 1954] [Schlegel, 
1960] [McNeil et al., 2000]. Thus, pheochromo-
cytoma should be considered in patients with 
hypertension, but generally only when secondary 
causes of high blood pressure are being consid-
ered or when there are other symptoms or signs of 
catecholamine excess that can alert the physician 
to the tumor. Prevalence of pheochromocytoma is 
much higher, at 4.2 to 6.5%, in patients screened 
for the tumor due to an incidentally discovered 
adrenal mass [Mantero et al., 2000] [Mansmann 
et al., 2004]. All patients with adrenal masses 
should therefore be screened for pheochromocy-
toma, irrespective of the presence of hypertension 
and symptoms of catecholamine excess.
Diagnosis and localization
Diagnosis
As now widely recommended [Pacak et al., 
2007c], initial screening of pheochromocytoma 
should always include either or both measure-
ments of urinary or plasma metanephrines, these 
metabolites comprising normetanephrine and 
metanephrine, the respective degradation prod-
ucts of the catecholamines, noradrenaline (NA) 
and adrenaline (A). Measurements of plasma free 
metanephrines have been shown by numerous 
independent studies to provide diagnostic sensi-
tivity exceeding 96% with specificity between 85 
to 100% [Pacak et al., 2007c]. To minimize false-
positive results blood samples should be drawn 
under stress free conditions in the supine position. 
Urinary fractionated metanephrines provide an 
alternative approach with similar diagnostic sensi-
tivity [Brain et al., 2006]. Diagnostic specificity at 
cut-offs for optimal sensitivity have, however, 
been reported as low as 45% for patients tested 
because of signs and symptoms [Lenders et al., 
2002], this representing a limitation of urinary 
measurements. Urinary fractionated metane-
phrines are also commonly measured after a 
deconjugation step and therefore reflect different 
metabolites from the free metanephrines in 
plasma. Nevertheless the urinary tests are com-
monly available and their high diagnostic sensi-
tivity provides justification for use during initial 
screening, albeit with likelihood to rule out 
subsequent false-positive results.
Metanephrines in plasma or urine can be meas-
ured by three different methods. Measurement 
by liquid chromatography with electrochemical 
detection (LC-EC), although a well established 
method with high accuracy and precision, is a 
technically demanding procedure. Immunoassays, 
which are easily established and commonly 
used in European laboratories for hormone 
measurements, have disadvantages of calibration, 
accuracy and precision problems [Singh et al., 
2007] [Pillai et al., 2010] [Mullins et al., 2011]. 
In US and many other laboratories, liquid chro-
matography with tandem mass spectrometry 
(LC-MS/MS) has fast become the preferred 
method for determination of plasma and urinary 
metanephrines. This high-throughput method 
provides a precise, rapid, and specific method for 
biogenic amine measurements, but does require 
a large capital outlay and significant technical 
expertise [Lagerstedt et al., 2004].
Localization of pheochromocytoma
Once a pheochromocytoma is confirmed bio-
chemically, the next step is to locate the tumor 
[Figure 1]. If a pheochromocytoma is located 
extra-adrenally it is defined as a paraganglioma. 
Localization is usually achieved by either com-
puted tomography (CT) or magnetic resonance 
imaging (MRI) of the abdomen, with a sensitivity 
of 90-100% and a specificity of 70-80% [Maurea 
et al., 1993] [Francis et al., 1996] [Maurea et al., 
1996] [Lenders et al., 2005]. However, specificity 
of MRI or CT imaging has been reported by 
some investigators as low as 50% [Ilias et al., 
2004]. Unsatisfactory results, for example, may 
also be obtained in patients with SDHB and 
SDHD mutations in whom paragangliomas can 
be located at extra-abdominal locations. For this 
reason, algorithms that include whole body MRI 
as part of the combination of conventional and 
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functional imaging have been proposed for disease 
localization and confirmation.
Imaging by 123I-MIBG (metaiodobenzylguani-
dine) scintigraphy provides a widely used second-
ary imaging modality [Shapiro et al., 1985] [Pacak 
et al., 2001a]. This test has a high specificity and 
therefore should be considered in all patients with 
findings of adrenal tumors by conventional imag-
ing. If the mass shows up on MIBG, the diagnosis 
is confirmed justifying surgical resection [Bravo, 
1994] [Shapiro et al., 1995] [Sisson et al., 1999b] 
[Miskulin et al., 2003]. MIBG can also point to 
additional lesions not indicated by conventional 
imaging in patients with metastatic disease or 
multifocal disease associated with mutations of 
disease-susceptibility genes. However, MIBG has 
lower sensitivity for detection of extra-adrenal 
tumors than adrenal tumors [Bhaita et al., 2008]. 
MIBG is also nevertheless not as sensitive for 
detection of metastases compared to some other 
functional techniques [Timmers et al., 2009].
If available, positron emission tomography, ideally 
combined with CT (PET/CT), and utilizing a 
range of labelled ligands provides an alternative 
functional imaging approach with improved resolu-
tion over scintigraphic methods. Such methods are 
particularly useful when MIBG scintigraphy, CT or 
MRI fail to locate the tumor. Radiotracers which 
have proven useful include 18F-fluorodopamine 
[Pacak et al., 2001b], especially in the diagnosis of 
metastatic disease [Ilias et al., 2003], 18F-fluorodopa 
[Hoegerle et al., 2002], 11C-hydroxyephedrine 
[Trampal et al., 2004] [Pacak et al., 2004], 
and 68Ga-DOTATOC (tetraazacyclododecane-
tetraaceticacid-tyr3-octreotide) [Kroiss et al., 
2011]. Accumulating evidence suggests that 
18F-fluorodeoxyglucose (FDG) is particularly valu-
able for detecting metastases in malignant pheo-
chromocytoma and paraganglioma [Timmers et 
al., 2007b] [Timmers et al., 2009]. Adrenal venous 
sampling can be useful for localization of the tumor 
in selected cases when imaging results remain 
equivocal [Darr et al., 2011].
Considerations for management of 
hereditary syndromes
Advances in genetics
Classically, three syndromes are associated with 
pheochromocytoma, namely von Hippel Lindau 
(VHL) syndrome, multiple endocrine neoplasia 
type 2 (MEN2) and neurofibromatosis type 1 
(NF1) [Neumann et al., 1993] [Bryant et al., 
2003]. After germline mutations of succinate 
dehydrogenase (SDH) subunit genes were identi-
fied as responsible for familial paraganglioma, it 
became apparent that up to 30% of all pheo-
chromocytomas were due to genetic mutations 
[Neumann et al., 2002] [Burnichon et al., 2011].
Mutations of all four SDH subunits are now 
identified as causes of hereditary paraganglio-
mas: These include SDHA [Burnichon et al., 
2010] [Korpershoek et al., 2011], SDHB [Astuti 
et al., 2001], SDHC [Niemann et al., 2000] and 
SDHD [Baysal et al., 2000]. Together with other 
mutations such as of the succinate dehydroge-
nase assembly factor 2 (SDHAF2) [Kunst et al., 
2011] [Korpershoek et al., 2011], the transmem-
brane protein 127 (TMEM127) [Qin et al., 2010] 
and the MAX-gene [Comino-Mendez et al., 
2011], there are now 10 known genes in which 
mutations predispose to pheochromocytoma and 
paraganglioma.
Screening for pheochromocytoma in mutation 
carriers. With the exception of mutations 
associated with low disease penetrance (e.g., 
NF1), all patients identified with a genetic 
mutation require periodic screening for pheo-
chromocytoma and must be tracked and traced 
lifelong on a usually recommended yearly basis. 
Surveillance for pheochromocytoma and para-
ganglioma should be individualized according to 
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Figure 1. Algorithm for localization and confirmation 
of pheochromocytoma and paraganglioma
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the underlying genetic mutation. In particular, 
biochemical screening should account for the 
distinct mutation-dependent profiles of catechol-
amine production, best assessed by differences 
in plasma normetanephrine, metanephrine and 
methoxytyramine [Eisenhofer et al., 2011b].
Pheochromocytomas in VHL tumors are charac-
terized by a solely noradrenergic biochemical 
phenotype so that, screening should be directed 
to measurements of normetanephrine. Adrenal 
tumors are common and the tumor is bilateral in 
40% of the cases [Neumann et al., 2002], but 
extra-adrenal occurrence is possible and should 
always be considered in VHL syndrome. In con-
trast tumors in patients with MEN2 and NF1 
also produce epinephrine, so that management of 
these patients should be directed to identification 
of increases in both metanephrine and norme-
tanephrine. Since tumors are invariably intra-
adrenal [Lairmore et al., 1993] imaging studies 
should focus mainly on the adrenals, with MIBG-
scanning a particularly useful functional imaging 
modality due to highly active uptake of the agent 
by these tumors.
Tumors due to SDHB and SDHD mutations are 
somewhat similar to those due to VHL mutations 
in that they lack significant epinephrine produc-
tion, so are not characterized by increases in 
metanephrine [Timmers et al., 2007a] [Eisenhofer 
et al., 2010]. However, these tumors often 
produce dopamine (D). Thus, in addition to 
measurement of normetanephrine, management 
of these patients can be improved by extending 
biochemical testing with measurements of dopa-
mine and its metabolite methoxytyramine.
Extraadrenal tumors predominate in patients 
with SDHB or SDHD mutations, so imaging 
studies should be extensive, best achieved by 
whole body MRI. Head and neck paraganglio-
mas, which are particularly common in SDHD 
mutation carriers, should always be considered and 
are best screened for using magnetic resonance 
angiography [Neumann et al., 2002] [Neumann 
et al., 2004]. Periodic screening with whole body 
MRI has been advocated in patients with SDHB 
mutations since tumors are particularly primi-
tive and abdominal paragangliomas have been 
reported that do not produce any significant 
increases in normetanephrine or methoxytyramine 
[Timmers et al., 2008]. Tumors in SDHB muta-
tion carriers also have a high potential for malig-
nancy, demanding particular close and careful 
management of these patients [Amar et al., 2005b] 
[Brouwers et al., 2006]. Where malignancy is 
suspected, PET scanning with 18F-FDG is the 
preferred technique [Zelinka et al., 2008].
Screening for genetic mutations. Due to the high 
prevalence of germline mutations in pheochro-
mocytoma and paragangliomas it is generally rec-
ommended that possible mutations be considered 
in all patients with the tumors. The extent of 
testing remains highly debatable, but it is now 
clear that management of this testing should 
always take into account clinical features that can 
point to a particular mutation [Grossman et al., 
2006] [Pacak et al., 2007b].
Of primary importance for individualized genetic 
testing is to first check for any clinical stigmata 
suggestive of a particular syndrome or whether 
there may be any relatives with a history of or 
suggestive of the tumors or a particular syn-
drome. Testing then should be directed to those 
particular genes. In the absence of a family his-
tory or characteristic clinical signs, a younger age 
at presentation carries a higher likelihood of 
underlying genetic defect [Neumann et al., 2002] 
[Amar et al., 2005b]. Generally, VHL, SDHB 
and SDHD mutations present at a younger age 
compared with tumors in patients with NF1 and 
MEN2 [Eisenhofer et al., 2011a]. Bilateral adre-
nal tumors or multifocal extra-adrenal tumors 
carry a particularly high risk of germ line muta-
tions that should always be explored.
Apart from the above factors, other considera-
tions that can be used to point to mutations in 
the management of patients include locations of 
the tumor, catecholamine biochemical profiles 
and presence of metastatic disease [Table 1]. 
Mutations of RET, TMEM127 and MAX genes 
are rarely associated with extra-adrenal primary 
tumors [Yao et al., 2010] [Comino-Mendez et al., 
2011], the presence of which dictates emphasis of 
genetic testing on mutations involving genes for 
succinate dehydrogenase subunits, which more 
often give rise to extra-adrenal than adrenal 
tumors. Patients with SDHB and SDHD muta-
tions in particular often have tumors that produce 
methoxytyramine, usually with elevations of nor-
metanephrine, but no or relatively insignificant 
elevations of metanephrine. Thus, in patients 
with these catecholamine biochemical profiles 
mutations of SDHB and SDHD genes should 
be considered. These mutations need not be con-
sidered for patients with tumors that produce 
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metanephrine. Similarly, VHL mutations do not 
lead to tumors that produce epinephrine or 
metanephrine, so that this gene need not be con-
sidered in patients with tumors associated with 
increases in metanephrine. In contrast, pheochro-
mocytomas in MEN 2 always produce increases 
in metanephrine, so that RET mutations should 
be considered in patients with these tumors.
Immunohistochemical staining for SDHB in 
resected tumor samples can also provide useful 
information to guide genetic testing, which for 
SDHB or SDHD mutations is only indicated in 
SDHB negative tumors [Van Nederveen et al., 
2009]. SDHB gene mutations should also be 
strongly suspected in patients with metastatic 
disease, but not those where disease is associated 
with large increases in metanephrine.
Complications and potential pitfalls 
in the treatment of the discovered 
pheochromocytoma
Preoperative considerations
Once a pheochromocytoma has been diagnosed 
and localized the next step is preparation for sur-
gery. This ideally should be an interdisciplinary 
task involving endocrinologists, radiologists, 
nuclear medicine physicians, anaesthesiologists 
and surgeons but may also involve oncologists, 
cardiologists and clinical chemists. The presence 
of potential metastatic disease should always be 
considered and ruled out, since any indication of 
this is likely to impact treatment options beyond 
surgery. Patient management related to extent 
and choice of functional imaging to check for 
additional tumors or metastases should take 
into account stratification of risk for malignancy. 
Patients with large or extra-adrenal tumors, 
tumors associated with elevated plasma concen-
trations of methoxytyramine or due to SDHB 
mutations all have increased likelihood of meta-
static disease [Tischler, 2008] [Eisenhofer, 
2011c]. Risk increases when these factors associ-
ate in any combination and can be used to justify 
more extensive functional imaging to rule out 
metastases than might otherwise be considered. 
With no evidence of malignant disease, surgery 
is justified.
Due to the effects of circulating catecholamines on 
the cardiovascular system and possible preexisting 
cardiomyopathy in a patient with pheochromocy-
toma [Schurmeyer et al., 1997], cardiovascular 
function should be evaluated prior to surgery. 
This may include an electrocardiogram, ambula-
tory blood pressure monitoring to assess blood 
pressure variations, supine and standing blood 
pressure measurements to evaluate for postural 
hypotension, and echocardiography to determine 
heart dimensions and function.
Table 1. Main features of hereditary mutations associated with pheochromocytoma, paraganglioma, and 
sporadic disease
Onset Adrenal Bilateral Extra-adrenal Malignancy Type
Sporadic 70% 40-50 90% 10% 10% 10%  
Hereditary 30%  
Gene Chromosome  
  
SDHB 1p36.13 30 28% multifocal 59% 
abdominal 
thoracic
60% NA/D
SDHD 11q23 30 53% multifocal 79% 
head&neck
17% NA/D
VHL 3p25-26 30 88% 40% 12% 4% NA
NF1 17q11.2 40 84% 10% 6% 11% NA/A
RET 10q11.2 40 100% 38% rare 4% NA/A
SDHA 5p15 n.a. n.a. n.a. n.a. n.a. Unknown
SDHAF2 11q12.2 30 n.a. n.a. extraadrenal n.a. Unknown
SDHC 1q23.3 n.a. rare rare rare rare Unknown
TMEM127 2q11.2 n.a. adrenal bilateral n.a. 5% Unknown
MAX-gene 14q23 n.a. n.a. n.a. n.a. n.a. Unknown
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Cardiac arrhythmias due to sudden catecholamine 
release during surgery and cardiac ischemia may 
occur [Quezado et al., 1992], and preexisting 
coronary artery disease may be aggravated by 
sudden vasospasms due to catecholamine release 
[Mannelli, 2006]. Coronary vasospasms may 
mimick cardiac ischemia [Liao et al., 2000], 
and direct catecholamine action may lead to 
pulmonary oedema [Tauzin-Fin et al., 1999]. 
Also, cerebrovascular accidents are a severe 
complication of hypertensive crisis in patients 
with pheochromocytoma.
Although some have suggested otherwise 
[Lentschener et al., 2011], it remains widely rec-
ommended that appropriate medications should 
always be employed prior to surgery to block the 
effects of circulating catecholamine in all patients 
with catecholamine-producing tumors [Russell 
et al., 1998] [Kinney et al., 2000]. There are no 
official guidelines on the types of blocking drugs, 
with both alpha-adrenergic blockers and calcium 
channel blockers representing the main medica-
tions chosen for the purpose [Tokioka et al., 1988] 
[Boutros et al., 1990] [Young, 1997] [Ulchaker 
et al., 1999] [Van Der Horst-Schrivers et al., 
2006] [Pacak, 2007d].
Both slow-release nifedipine, a dihydropyridine 
calcium-channel blockers and diltiazem, a non-
dihydropyridine calcium-channel blocker [Tokioka 
et al., 1988], have been described to control hyper-
tension in pheochromocytoma. Immediate-release 
nifedipine, however, must be avoided because of 
potentially life-threatening cardiac accidents asso-
ciated with this formulation. Otherwise calcium 
channel blockers can safely be used also in the 
cardiovascular patient, mitigating coronary vasos-
pasms due to sudden noradrenaline release [Bravo 
et al., 2003]. Nifedipine is given at a dose of 30-60 
mg once daily, doses up to 120 mg per day have 
also been described [Proye et al., 1989].
Most usually pre-operative blockade of catechola-
mine action employs the irreversible non-selective 
alpha-adenergic receptor, phenoxybenzamine. 
The drug is titrated according to patient needs. 
The starting dose is 10 mg twice a day, with step-
wise increases of 10 to 20 mg every 2-3 days until 
the final dose of 1 mg/kg of body weight is reached. 
This dose is given in three divided doses over the 
day and is normally reached within 10-14 days, 
while the patient can be followed on an outpatient 
basis [Witteles et al., 2000]. Blood pressure 
monitoring should be ensured two to three times 
a day, but even more important is measurement 
of standing blood pressure to gauge eventual 
orthostatic hypotension. Clinical signs of the 
optimal dose are a stuffy nose and slight dizziness 
due to postural hypotension.
Alternatively to phenoxybenzamine, the selective 
and reversible alpha1-blocker doxazosin may be 
used [Bravo et al., 2003]. Doxazosin is started at 
a dose of 1 mg and increased thereafter to 32 mg 
once a day. In contrast to phenoxybenzamine, 
strong catecholamine bursts can displace doxazo-
sin from its receptor binding site and thus reduce 
efficacy. The advantage on the other hand is 
thought to be a reduced hypotensive response 
after surgery but this issue still remains unre-
solved [Kinney et al., 2002] [Kocak et al., 2002] 
[Prys-Roberts et al., 2002]. In our outpatient set-
ting, we normally use phenoxybenzamine for the 
preoperative treatment. Exceptions from this 
routine are the operation of head and neck para-
ganglioma especially if this tumor does not pro-
duce catecholamines or only dopamine [Mannelli, 
2006].
In order to reduce tachycardic reflex responses, 
a low dose beta-blockade can be initiated in 
patients with evidence of tachycardia before sur-
gery. Cardioselective beta1-blockers such as 
metoprolol at 50 to 100 mg, bisoprolol at 5-10 
mg or atenolol at 25-50 mg once daily [Prys-
Roberts, 2000] are recommended. Intraoperative 
tachycardias may be controlled by esmolol [Gray, 
1988]. Although labetalol has been used in the 
pharmacological treatment of pheochromocytoma 
[Van Stratum et al., 1983] [Yabe et al., 1987], its 
use is controversial [Reach et al., 1980]. Briggs 
et al. reported about a hypotensive reaction in a 
patient in postural position and a reactive hyper-
tensive crisis in supine position after labetalol, 
cautioning against the use of this drug in pheo-
chromocytoma [Briggs et al., 1978].
Alpha-methyl-para-tyrosine (metyrosine) has been 
used for additional preoperative treatment of 
pheochromocytoma [Perry et al., 1990], but 
today is primarily relegated to patients in whom 
disease is extensive and accompanied by large 
increases in catecholamines. Metyrosine blocks 
catecholamine biosynthesis by inhibiting the con-
version of tyrosine to L-dopa [Sjoerdsma et al., 
1965]. Usually metyrosine is started with an oral 
dose of 250 mg 3 to 4 times per day and gradually 
increased to a total dose of 1,5 to 4,0 g/d [Pacak 
et al., 2007a].
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Acute hypertensive attacks can be managed with 
the short acting alpha-blocker phentolamine as 
an infusion of e.g. 100 mg in 500 ml of 5% dex-
trose in water with 1mg/min [Pacak et al., 2007a]. 
Other drugs in these emergency cases proven 
useful are vasodilating agents such as nitro-
prusside and nitroglycerin [Prys-Roberts, 2000] 
[Kinney et al., 2002] [Prys-Roberts et al., 2002] 
as well as urapidil in Europe [Tauzin-Fin et al., 
2004]. Interestingly good results in treating 
hypertension in patients with pheochromocy-
toma have been achieved with magnesium sul-
phate and therefore magnesium may be tried as a 
second line therapy for blood pressure control 
[James, 1989]. The action of magnesium is thought 
to be an inhibition of catecholamine release from 
the normal adrenal gland and from adrenergic 
nerve terminals [Douglas et al., 1963] [Von Euler 
et al., 1973].
Anaesthesia – aspects
Premedication with a benzodiazepine can be 
employed in patients with pheochromocytoma 
and no premedication has been shown to be 
superior to others [Kinney et al., 2002]. For 
operation usually general anaesthesia is chosen. 
For induction, thiopental has been used with 
success [Desmonts et al., 1984] and seems to 
decrease plasma catecholamine levels [Joyce et 
al., 1983]. Also propofol and etomidate have 
been used with etomidate providing more cardio-
vascular stability [Hull, 1986]. Causing indirect 
catecholamine release, ketamine, morphine or 
meperidine, as well as droperidol [Sumikawa 
et al., 1977] and ephedrine are not recommended 
[Kinney et al., 2002].
For muscle relaxation, vecuronium [Gencarelli 
et al., 1981], pancuronium [Desmonts et al., 
1984] and atracurium [Prys-Roberts, 2000] 
have been used, with atracurium possibly caus-
ing catecholamine release via histamine. As this 
also applies for tubocurarine and curare, and 
gallamine causing vagolytic effects, all those 
drugs should be avoided in patients with pheo-
chromocytoma. Pancuronium has been used 
with success in the past but has been associated 
with severe hypertension [Jones et al., 1981]. 
Because of its cardiac side effects, succinylcho-
line should be avoided [Stoner et al., 1968]. Also, 
succinycholine may result in muscle fascicula-
tion with ensuing mechanical stimulation of 
the tumor, and potentially life threatening cat-
echolamine bursts [Desmonts et al., 1984].
Regarding maintenance of anesthesia with volatile 
agents, sevoflurane [Kinney et al., 2002], isoflu-
rane [Kinney et al., 2000] and enflurane [Janeczko 
et al., 1977] can safely be used. Desflurane causes 
sympathetic activation but has also been adminis-
tered [Lippmann et al., 1994].
Operation - aspects
Today, pheochromocytomas of the abdomen 
normally can be operated on laparoscopically 
[Janetschek et al., 1998] [Gill, 2001]. Single access 
retroperitoneoscopic adrenalectomy (SARA) may 
be an elegant alternative [Walz et al., 2010]. The 
laparoscopic approach, together with adequate 
preoperative management, reduces periopera-
tive mortality to 2.4% [Plouin et al., 2001]. It also 
reduces morbidity, hospital stay and costs 
[Fernandez-Cruz et al., 1996] [Sprung et al., 
2000], and is feasible and safe in solitary, bilateral, 
multiple, and recurrent pheochromocytoma [Walz 
et al., 2002] [Jaroszewski et al., 2003].
Partial adrenalectomy has been recommended in 
hereditary phechromocytoma to avoid adrenal 
insufficiency and lifelong hormone replacement 
therapy [Neumann et al., 1999] [Walther et al., 
2000]. However partial adrenalectomy may pre-
dispose patients to an increased risk of recurrent 
disease. When performed in hereditary disease 
[Brauckhoff et al., 2004], recurrence rate has 
been described in the range between 21% and 
60% [Lee et al., 1996] [Inabnet et al., 2000]. 
Furthermore, partial adrenalectomy may not 
always ensure cortisol independency postopera-
tively [Yip et al., 2004]. Therefore the benefits 
and risks of partial and total adrenalectomy must 
be discussed with the patient in each single case.
Open surgery may be indicated, when tumors 
are multiple or very large [Vargas et al., 1997] but 
even tumors sized more than 9 cm may safely be 
removed laparascopically depending on the 
experience of the surgeon [Pacak et al., 2007a]. 
Nevertheless, it is now becoming increasingly 
clear that risk of malignant disease increases with 
tumor size [Eisenhofer, 2011c]. Minimizing risk 
of spillage associated with laparoscopic surgery 
may therefore be important to consider with large 
tumors or for those associated with increased risk 
of malignancy due to other established risk factors 
(i.e., SDHB mutations, extra-adrenal locations). 
Difficult extra-adrenal operative sites include 
tumors located in the bladder, the chest or the 
head and neck [Manger, 2006].
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Since head and neck paragangliomas rarely 
secrete catecholamines these tumors mostly do 
not require preoperative treatment. The main risks 
are related to operative difficulties. Complications 
include intraoperative nerve lesions, especially of 
the recurrent laryngeal nerve with subsequent 
hoarseness and difficulties of speaking and breath-
ing. Other cranial nerves may be injured causing 
impairment of swallowing, hearing or facial mus-
cle paralysis. In some cases, loss of blood pressure 
control due to baroreflex trauma may occur 
[Mannelli, 2006].
Postoperative considerations
Main challenges of the immediate postoperative 
period are blood pressure instability and heart rate 
control, as well as symptomatic hypoglycaemia, 
necessitating close patient monitoring for at 
least 24 h after operation [Mannelli, 2006]. Loss 
of peripheral vasoconstriction after operation may 
lead to hypovolemic hypotension, despite preop-
erative loading with normal saline. The amount of 
fluid required may be as large as 6-7 liters within 
the first two days after operation. Also, the effect of 
irreversible preoperative alpha-blockade may 
persist for more than 36 hours postoperatively 
[Bergman et al., 1978]. Under these circumstances 
hypotension may be nor- and adrenaline resistant, 
and vasopressin may be needed for blood pressure 
control [Augoustides et al., 2004].
Hypoglycaemia may occur because of rebound 
hyperinsulinemia [Isles et al., 1983] [Ostenson 
et al., 1989], and may be aggravated by prolonged 
postoperative alpha-blockade. Also, overt hypogly-
caemic reactions may be masked due to impaired 
gluconeogenesis and glucogenolysis after beta2-
receptor blockade [Kinney et al., 2002]. Therefore, 
close monitoring of blood glucose levels is manda-
tory, and prompt dextrose-infusions should be ini-
tiated when necessary [Meeke et al., 1985]. If both 
hypotension and hypoglycaemia occur in a patient 
after bilateral partial or complete adrenalectomy 
[Costello et al., 1988], suspicions about hypocorti-
solism and its most severe form, Addisonian 
crises should be raised, and plasma and urinary 
cortisol and plasma adrenocorticotropic hormone 
(ACTH) levels measured. If confirmed immediate 
steroid replacement should be started [Pacak 
et al., 2007a].
Incomplete tumor removal, coexisting essential 
hypertension, volume overload, autonomic insta-
bility, postoperative pain or accidental ligation of 
the renal artery may result in postoperative 
hypertension [Engelman, 1977] [Young, 1997] 
[Pacak et al., 2007a]. If hypertension persists 
the underlying cause should be determined and 
therapy instituted accordingly.
Follow-up
To ascertain that resection was complete and suc-
cessful, biochemical testing should be undertaken 
dependent on the patient´s recovery within 2-6 
weeks after surgery. As recurrence rates of up to 
14% have been reported in pheochromocytoma 
and of up to 30% in extra-adrenal disease [Amar 
et al., 2005a], lifelong follow up is recommended 
in all patients [Scott et al., 1984] [Jaroszewski 
et al., 2003]. Also, tumors may recur beginning 
from one year for up to 16 years after initial 
diagnosis and operation [Plouin et al., 1997]. 
Therefore all patients with histologically proven 
pheochromocytoma or paraganglioma should be 
referred to and followed in specialized centers to 
ensure appropriate follow-up measurements 
[Mannelli, 2006]. Yearly follow up is also indi-
cated in patients who are not willing to be or 
cannot be operated on for reasons such as previ-
ous adrenalectomy, putting them at increased 
risk for lifelong hormone replacement therapy, 
or because of an unacceptably high patient mor-
bidity. In patients with sporadic pheochromocy-
toma follow up should be 10 years at least. 
Patients with either extra-adrenal disease or 
familial pheochromocytoma should be screened 
indefinitely in an individualized manner on a 
yearly basis [Lenders et al., 2005]. Follow up 
visits every 6 months are indicated in patients 
with metastatic pheochromocytoma.
The patient with malignant 
pheochromocytoma and 
paraganglioma
Although attempts have been made to identify 
malignant pheochromocytoma by histomor-
phologic features [Thompson, 2002], proof of 
malignant disease to date relies on pathological 
confirmation of tumor metastases at sites where 
chromaffin tissue normally is absent, including 
bones, lungs, liver and lymph nodes. There are, 
however, several factors that can be used to pre-
dict future development of malignant disease. 
The presence of an SDHB mutation represents 
the single most important predictor for increased 
risk of malignancy [Gimenez-Roqueplo et al., 
2003]. As shown by Eisenhofer [Eisenhofer, 
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2011c], the high risk of malignancy assocociated 
with SDHB tumors entirely reflects both the pre-
dominant extra-adrenal locations and large size 
reached by tumors in patients with these muta-
tions. Both extra-adrenal location and large tumor 
size are independent factors that contribute 
to increased risk of malignancy. Additionally, 
elevations of methoxytyramine, the O-methylated 
metabolite of dopamine, indicate an increased 
likelihood of metastases [Eisenhofer, 2011c].
Treatment options of malignant disease are limited. 
Disappointing results with only temporary remis-
sions lasting for up to two years [Eisenhofer et al., 
2004] have been obtained with i.v. cyclophospha-
mide, vincristine and dacarbazine combination 
chemotherapy [Averbuch et al., 1988]. Future 
therapy options may include LB1, a small mole-
cule inhibitor of serine/threonine protein phos-
phatase 2A (PP2A), combined with temzolamide 
[Martiniova et al., 2011] or sunitinib [Joshua 
et al., 2009]. Symptomatic medical therapy is 
directed towards control of blood pressure and 
largely follows preoperative disease management 
rules. In addition alpha-methyl-para-tyrosine has 
been shown effective in case of high levels of 
plasma catecholamines [Decoulx et al., 1987].
131MIBG-radiotherapy either alone or in combi-
nation with chemotherapy has been reported to 
result in partial tumor remission [Sisson et al., 
1999a]. However, progressive disease has also 
been reported using this treatment modality 
[Schlumberger et al., 1992]. It is presently 
unclear, whether higher doses of radiation might 
improve patient survival [Rose et al., 2003]. The 
low remission rate observed may at least in part 
be due to the fact that malignant pheochromo-
cytoma do not readily accumulate 131MIBG 
[Ilias et al., 2003].
Surgery is restricted to debulking strategies as 
there is no curative approach [Eisenhofer et al., 
2004]. Surgery can reduce the total amount of 
the catecholamine producing mass and the dele-
terious results of elevated catecholamines on the 
heart [Mishra et al., 2000]. Furthermore, surgery 
can remove lesions that are life threatening due 
to their location [Nonaka et al., 2000]. Finally, 
surgery can serve as an adjuvant measure prior 
to radiotherapy or chemotherapy. Nevertheless, 
prognosis of malignant disease is poor. In a post-
operative survival study, 5 year survival rate has 
been estimated to be 20%, while no patient was 
alive ten years after surgery [John et al., 1999]. 
In one single report a patient was alive more 
than 25 years after initial diagnosis [Yoshida 
et al., 2001].
Pheochromocytoma in pregnancy - 
special considerations
With a prevalence of 1 in 50,000, pheochromocy-
toma is only rarely seen in pregnancy, where it 
shares two main symptoms with pre-eclampsia, 
namely spells of hypertension [Mannelli et al., 
2002] and headaches. Suspicions of pheochromo-
cytoma should be raised in any pregnant woman 
with new onset hypertension [Manger, 2009], 
especially in the first half of pregnancy [Lenders, 
2011]. Hypertensive crisis may compromise pla-
cental circulation while placental enzymes protect 
the fetus from direct catecholamine actions [Brunt, 
2001] [Pacak et al., 2007a].
Phenoxybenzamine in the pretreatment period 
before surgery seems to be safe for the fetus 
[Ahlawat et al., 1999]. In hypertensive crisis, phen-
tolamine can be used with 1 mg/min, as well as 
sodium nitroprusside as a final backup but only at 
a low dose and not over a prolonged time period 
to avoid fetal cyanide poisoning [Molitch, 1992]. 
Also, control of hypertension may be achieved 
with magnesium sulphate provided adequate 
magnesium levels are reached [James et al., 1988]. 
Care should be taken to avoid hypotension since 
similar to hypertension, this can compromise 
placental circulation [Griffen et al., 1969].
Special regards are necessary concerning diag-
nosis and tumor localization. The clonidine test 
cannot be performed in pregnant women, but 
measurement of urinary metanephrines after 
overnight sampling may be a useful alternative 
[Sullivan et al., 1975] [Peaston et al., 1996]. 
Abdominal ultrasound has a low diagnostic 
sensitivity especially for small tumors. Magnetic 
resonance tomography with gadolinium enhance-
ment is the imaging procedure of first choice. 
However confirmation of a mass as pheochromo-
cytoma or paraganglioma by scintigraphy is not 
feasible, leaving physicians and the mother in 
doubt of its origin.
Due to its infrequent occurrence, management 
of pheochromocytoma in pregnancy remains a 
medical challenge. If unrecognized, the risk of 
miscarriage, and of both maternal and fetal 
mortality is high, with reported mean ranges of 40 
through 48% and 44 through 56%, respectively 
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[Griffen et al., 1969] [Schenker et al., 1982] 
[Pacak et al., 2007a], while rapid diagnosis 
reduces these rates approximately by half 
[Grodski et al., 2006]. However, despite unques-
tionable progress in recent years still antenatal 
diagnosis is made in only 30% to 50% of patients. 
These are sobering results considering that 
with antenatal diagnosis maternal mortality 
rate decreases nearly to zero and mortality of the 
unborn child to 15-18%, respectively [Harper 
et al., 1989] [Oishi et al., 1994].
There is general agreement that the tumor should 
be resected before the third trimenon and also 
that the method of choice should be laparascopy 
[Demeure et al., 1998]. The risk of spontaneous 
abortion is greatest in the first trimenon [Yumi, 
2008]. In the third trimenon, cesarean section 
should be performed prior to tumor removal 
[Manger et al., 1996]. The issue of whether both 
operations should be carried out simultaneously 
is unsettled, unless in case of uncontrolled hyper-
tension, hemorrhage or other emergency situa-
tions [Pacak et al., 2007a].
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